1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| 82VS Seed Fund, LP | March 2024 | $20M | $20M | 35 |
| 82VS Seed Fund I, LPFiled to raise in 2024, with no closing reported yet. | 2024 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Errik Anderson | Selective | Biotech & pharma | 12 | 2 |
Classified sectors of 82vs’s own portfolio companies, based on 11 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of 82vs’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| GTP AW | 12 | Aakha Biologics, Alloy Therapeutics, Alumni Ventures Group, Angiex, Arsanis, Avitide, Cantai Therapeutics, Compass Therapeutics, Human Biotech, Mytide Therapeutics, Vernal Biosciences, Wheeler Bio |
| Green D Founders Fund 2014-i Lllp | 11 | Aakha Biologics, Alloy Therapeutics, Angiex, Arsanis, Avitide, Cantai Therapeutics, Compass Therapeutics, Human Biotech, Mytide Therapeutics, Vernal Biosciences, Wheeler Bio |
| Borealis | 2 | Avitide, Compass Therapeutics |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Caduceus Capital | 2 | Arsanis, Compass Therapeutics |
| Orbimed Asia Partners | 2 | Arsanis, Compass Therapeutics |
| Orbimed Genesis | 2 | Arsanis, Compass Therapeutics |
| Orbimed Global Healthcare | 2 | Arsanis, Compass Therapeutics |
| Orbimed Israel Partners | 2 | Arsanis, Compass Therapeutics |
| Orbimed New Horizons | 2 | Arsanis, Compass Therapeutics |
| Orbimed Partners | 2 | Arsanis, Compass Therapeutics |
| Orbimed Private Investments | 2 | Arsanis, Compass Therapeutics |
| SV Life Sciences | 2 | Arsanis, Avitide |
| 270 Healthcare Growth | 1 | Compass Therapeutics |
| MC Healthcare Ventures | 1 | Alloy Therapeutics |
| Polaris Partners | 1 | Arsanis |
A shared board seat: a company where filings name a 82vs partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
